Described herein is the androgen receptor modulator of formula (I)

##STR00001##

in the treatment of prostate cancer in combination with other therapeutic options and in the treatment of diseases or conditions that are amenable to treatment with the androgen receptor modulator, as well as pharmaceutical compositions and medicaments that include such compound.

The present invention relates to the use of radiopharmaceuticals having a radioactive half-life of less than 21 minutes, such as oxygen-15 labeled water (¾ .sup.150) in blood flow imaging using PET (Positron emission tomography) scanning technology. The invention also relates to the use of a system for preparing and injecting boluses of such radiopharmaceuticals.

The present invention relates to a composition for detecting hydrogen sulfide or measuring a concentration of hydrogen sulfide, and a composition comprising same as an effective ingredient for diagnosing or imaging in vivo inflammation, tissues having hypoxic damage, or cancer. The composition for detecting hydrogen sulfide or measuring a concentration of hydrogen sulfide according to the present invention, which comprises the compound represented by formula 1 (.sup.99mTc-alpha-hydroxy acid) having alpha-hydroxy acid labeled with .sup.99mTc, enables the detection or concentration measurement of hydrogen sulfide in in-vitro and in-vivo levels and, as such, can be advantageously used for detecting hydrogen sulfide and measuring a concentration of hydrogen sulfide and furthermore for discovering biological roles of hydrogen sulfide in vivo, especially, for detecting, imaging, and quantitatively measuring hydrogen sulfide in a disease selected from the group consisting of angiogenesis, inflammation, cancer, Alzheimer's disease, cardiovascular ischemia, and cerebrovascular ischemia, or in hypoxic tissues.

The invention provides a compound having the following structure:

D-DT-R,

wherein D is a dextran molecule or a charged dextran molecule having a molecular weight between about 50,000 and about 110,000 Daltons, DT is dodecane tetra-acetic acid (DOTA) or a conjugate base thereof, and R is a radioactive isotope. The invention also provides a method for treating body cavity cancer in a patient afflicted therewith, comprising administering an effective amount of a dextran-dodecane tetraacetic acid-radioactive isotope compound in a pharmaceutically effective vehicle.

The present invention relates to a stable pharmaceutical composition of tetrofosmin or pharmaceutically acceptable salts thereof. It also relates to a lyophilized non-radioactive kit which upon reconstitution with .sup.99mTc-pertechnetate solution gives a stable .sup.99mTc-tetrofosmin radiopharmaceutical composition. It also provides process for the preparation of said radiopharmaceutical compositions and their use in diagnostic imaging procedures. The compositions provide desirable technical attributes such as stability, high radiochemical purity (RCP) and desired bio-distribution.

A method of accumulating radium radionuclides, comprising providing a first solution including thorium radionuclides and a thorium-binding extractant, wherein the first solution does not bind to radium, allowing a portion of the thorium radionuclides in the first solution to decay into radium atoms and collecting radium atoms resulting from the decay. The collected radium atoms may be included in a solution in which brachytherapy sources are dipped, in a manner which collects the radium atoms onto the source.

The present invention relates to a composition for the diagnosis and treatment of recurrent thyroid cancer comprising recombinant human thyroid stimulating hormone (rhTSH) and a method for producing the recombinant human thyroid hormone. The method for producing recombinant human thyroid hormone according to the present invention can effectively produce rhTSH despite being cultured through fed-batch culture, and has a high purification yield and purity. Therefore, the recombinant thyroid stimulating hormone produced by the method can be usefully used for the diagnosis or treatment of recurrent thyroid cancer.

A process for producing a titanium-molybdate material is provided. The process includes a step of reacting a metal molybdenum (Mo) material in a liquid medium with a first acid to provide a Mo composition and combining the Mo composition with a titanium source to provide a TiMo composition. The TiMo composition can be pH adjusted with a base to precipitate a plurality of TiMo particulates.

The present invention relates to a stable pharmaceutical composition of tetrofosmin or pharmaceutically acceptable salts thereof. It also relates to a lyophilized non-radioactive kit which upon reconstitution with .sup.99mTc-pertechnetate solution gives a stable .sup.99mTc-tetrofosmin radiopharmaceutical composition. It also provides process for the preparation of said radiopharmaceutical compositions and their use in diagnostic imaging procedures. The compositions provide desirable technical attributes such as stability, high radiochemical purity (RCP) and desired bio-distribution.

There is provided a process for the preparation of a pharmaceutical composition comprising an .sup.18F-labelled gas selected from the group consisting of .sup.18F-labelled sulphur hexafluoride ([.sup.18F]SF.sub.6) and .sup.18F-labelled carbon tetrafluoride ([.sup.18F]CF.sub.4), comprising the steps: a) Filling a target with a gas mixture comprising a fluorinated gas selected from the group consisting of sulphur hexafluoride (SF.sub.6) and carbon tetrafluoride (CF.sub.4); b) Irradiating the gas mixture of step a) with protons with energies from 0.1 to 50 MeV. The pharmaceutical composition obtainable by the process and its uses in diagnosis, prognosis and lung function studies based on positron emission tomography (PET) are also claimed.